title: Design and mechanism of action of a novel cytotoxic 1,2,3-triazene-containing heterocycle, 3,5-dimethyl-pyrido-1,2,3,5-tetrazepin-4-one (PYRZ), in the human epithelial ovarian cancer cell line NIH:OVCAR-3 in vitro.
abstract: The mechanism of action of the novel heterocycle 3,5-dimethyl-pyrido-1,2,3,5-tetrazepin-4-one (PYRZ), structurally related to temozolomide, was studied in the human ovarian tumour cell line OVCAR-3. Our results showed that, despite its marked structural similarities to temozolomide, PYRZ presents properties that are atypical of 1,2,3-triazene-containing alkylating agents. In a Maxam-Gilbert DNA sequencing assay, PYRZ showed background levels of DNA alkylation, in contrast to temozolomide which strongly alkylated DNA preferentially at guanine residues. At high concentrations, PYRZ inhibited the synthesis of DNA, RNA and protein 3 h after treatment, in contrast to temozolomide which, in previous work, was found to preferentially inhibit DNA synthesis in OVCAR-3 cells. In cells exposed to PYRZ, alkaline sucrose density-gradient centrifugation showed a dose-dependent increase in DNA fragmentation only 12 and 24 h after treatment. PYRZ induced increasing accumulation of cells in late S and G2+M 6-24 h after treatment. This also contrasts with previous work that showed delayed cell cycle arrest induced by temozolomide in OVCAR-3 cells and in the murine leukaemia L1210 cells. Cell-killing kinetics by PYRZ showed a series of sigmoidal dose-response curves with 50-90% cell killing attained as early as 24 h after treatment in the 25-100 microM dose range. (IC50 clonogenic assay 18 microM). The results suggest that the mechanism of cell killing by PYRZ may be different from that of its parent drug temozolomide, and other alkyl-triazene-containing molecules of the same class.
authors.affiliation: Department of Oncology, McGill University, Montreal, Quebec, Canada.
authors.forename: B J
authors.initials: BJ
authors.lastname: Jean-Claude
authors.forename: A
authors.initials: A
authors.lastname: Mustafa
authors.forename: N D
authors.initials: ND
authors.lastname: Cetateanu
authors.forename: Z
authors.initials: Z
authors.lastname: Damian
authors.forename: J
authors.initials: J
authors.lastname: De Marte
authors.forename: R
authors.initials: R
authors.lastname: Yen
authors.forename: D
authors.initials: D
authors.lastname: Vasilescu
authors.forename: T H
authors.initials: TH
authors.lastname: Chan
authors.forename: B
authors.initials: B
authors.lastname: Leyland-Jones
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D001381:Azepines / Q000494:pharmacology*; D004247:DNA / Q000096:biosynthesis / Q000187:drug effects; D004249:DNA Damage; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014176:Protein Biosynthesis; D011725:Pyridines / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
chemical_list: C107841:3,5-dimethylpyrido-1,2,3,5-tetrazepine-4-one; D000970:Antineoplastic Agents; D001381:Azepines; D011725:Pyridines; D004247:DNA